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SUMMARY
Paul Ehrlich is one of the most notable figures in the world of science. Considered by many as the father of chemotherapy,
he was awarded the Nobel Prize in Physiology and Medicine in 1908 for his contributions to immunology. This document
outlines some of his most important findings, including those who led him to create his famous «magic bullets», precursors
of current chemotherapeutic agents.
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Paul Ehrlich: de las balas mágicas a la quimioterapia
RESUMEN
Paul Ehrlich es una de las figuras más notables en el mundo de la ciencia. Considerado por muchos como el padre de la
quimioterapia, sus aportes al campo de la inmunología lo hicieron acreedor al premio Nobel en Fisiología y Medicina en el año
1908. El presente escrito reseña algunos de sus hallazgos más importantes, incluyendo aquellos que lo llevaron a idear sus
famosas «balas mágicas», inspiradoras de la concepción de los agentes quimioterapéuticos actuales.
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A century after being awarded the Nobel Prize for
Physiology and Medicine, theories proposed by Paul
Ehrlich, far from being contested, have been refined and
consolidated so that under this influx, fields of medical
science as chemotherapy and serum therapy have
achieved immeasurable progress.
It is not free for Paul Ehrlich to be considered as a
central figure in the birth of chemotherapy and immu-
nology, apart from being a genius and messiah of
medicine, among many of the attributes that he has been
entitled to.
Son of Rosa Weigert and Ismar Ehrlich, who worked
for a lottery company as an office manager, Paul Ehrlich
was born in 1854 in Strehlen, territory of today Poland,
before East Prussia1-3.
During his stay through the universities of Wroclaw,
Strasbourg, Freiburg and Leipzig, the young medical
student developed a growing interest in using dyeing
chemicals, in order to stain animal cells and tissues. He
was particularly concerned by the fact that some types
of cells captured certain colors and excluded other1, the
«specific affinity» concept was probably being born in
his mind, foundation of the theories that he would post
later on the immune response and the experimental
therapeutics.
His doctoral thesis, conducted at the University of
Leipzig (1878), titled «Contributions to the theory and
practice of histological staining. Part I, the chemical
coloring concept. Part II, Chemical, technological and
histological concepts of aniline colors»4, as well as his
work on chemical dyes developed in the Medical Clinic
of Berlin, as Professor Frerichs’2 assistant, took him
later to discover salvarsan, the first known curative
medicine for syphilis.
In this same line, his first investigations on therapy
obtained special importance since Ehrlich showed interest
in elucidating the relationship between pharmacological
activity and the chemical structure of certain medici-
nes5.
In addition, he wanted to identify changes in the
therapeutic activity as a result of changes in the chemical
structure of certain compounds such as chemical dyes
that had been used so far only as diagnostic elements.
Then he applied the methylene blue for pain treatment,
due to its affinity for nervous tissue, as for that of malaria
in human beings, thanks to the affinity for plasmodium,
its causative agent.
Together with his assistant Shiga, studied the effect
of the red trypan dye on animals rather than on humans,
with the objective to treat some infections caused by
protozoa, such as trypanosomiasis. Certain experimen-
tal types of this disease were approached by Ehrlich
through the use of atoxyl, derivative of arsenic, whose
structural formula was established in the right way
thanks to their joint work with his colleague A. Bertheim2.
Likewise, Ehrlich investigated on the anesthetic
effects and the body distribution of cocaine, which he
attributed first to the presence of a particular functional
group, and second to the structure itself5.
By 1890, Ehrlich decided to focus its attention on the
nascent field of immunology, thanks to the invitation that
Robert Koch made to him to work in the newly created
Institute of Infectious Diseases in Berlin, where Emil
von Behring recently had discovered the antitoxins
against tetanus and diphtheria. However, antitoxins had
very low power, thus preventing their use in clinical
trials. Ehrlich was then in charge of developing a precise
method to measure the neutralizing power of each
antitoxin related to the standard and then he monitored
the power of the antitoxin produced by experimental
animals after by after injection of the toxin or toxoid5,6.
The final result consisted of standardized preparations,
very powerful and effective, which attracted great
interest in the serum therapy7. It is at this point of his
career where anyone can find the origin of Ehrlich’s
theory about lateral chains (side-chains), which actually
correspond to the immunoglobulins produced by B cells
and to the receptors of T cells.
Thus, It was proposed the existence of chemical and
non-biological interactions between toxin and antitoxin,
at the same time mediated the first by the presence of
two groups that he named toxophore and haptophore,
one of those had no toxic effect. According to his theory,
the toxophore bodies joined the cells through toxophil
bodies or «lateral chains». He argued that each cell had
a supply of lateral chains acting as well as cellular
receptors for toxins, or as antitoxins, as well, once they
were released into the blood6,8.
It is evident the correspondence existing between
Ehrlich’s theory on lateral chains and the interaction
between surface molecules present on B or T cells with
a specific antigen generating a clonal expansion that
leads to the release of immunoglobulins into the blood
stream.
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Despite the remarkable work done by Ehrlich towards
standardizing and conferring power to the antitoxins
discovered by Emil von Behring, the first Nobel Prize in
Physiology and Medicine in 1901 was awarded to the
last one2.
However, Professor Theodor Langhans of Berne
considered until the end that Paul Ehrlich was a potential
creditor for the award as written in a letter sent to the
Nobel Foundation9:
«As far as Paul Ehrlich is concerned, we need to
select his most important contributions, his
investigations on ricin (the «toxalbumin» or Lectin
of the castor bean), and on abrin (a powerful
phytotoxin of the precatory bean) going back to
1891 and following directly those of Behring’s.
Both of these toxins are related to the toxalbumoses
of bacterial origin and can be prepared in large
quantities and sufficient purity, which made it
possible for Ehrlich to investigate the problem of the
immune response with almost mathematical precision.
He arrived at the most interesting result that the
peak of immunity is reached after repeated doses on
the sixth day, comparable to the crises in pneumonia
or measles, and Ehrlich drew attention to the analogy
of the two situations. Better known are his
experiments in which he studied the transfer of
immunity from mother to child through lactation or
inheritance, investigations that he extended to
tetanus and swine erysipelas (Schweine-Rotlauf).
But even more important and most original are
Ehrlich’s views on the origin of antitoxins
(antibodies), his determination of the strength of the
serum against diphtheria in 1897 which he expanded
to tetanus.
He considers antitoxin (antibody) a normal
component of the cell with special «sidechains»
(Receptors) as part of the operational cellular
apparatus. The toxin of tetanus combines with such
a side chain with a profound effect on the entire cell
including the nucleus. As soon as the «sidechain» is
occupied by the toxin, a compensatory formation of
many new sidechains results, in Ehrlich’s views, in
an incredible abundance in which the excess
sidechains are ejected from the cells, enter the blood
stream and thus form the antiserum which neutra-
lizes the invading toxin...
This explanation is vastly different and much
more innovative than anything that has been thought
or written on the origin of antibodies so far. Ehrlich’s
ideas on toxoids (attenuated toxins) and epitoxoids
prove him to be an ingenious and highly original
thinker. His earlier hematological work, the
discovery of the mast cells, the histochemical staining
of living nerve fibers with methylene blue, his vital
staining, have by now been fully accepted and
clinically applied.
In short, I would like to nominate Behring in
Marburg and Paul Ehrlich in Frankfurt as prime
candidates for the first Nobel Prize.
I consider the two candidates as the most original
and felicitous investigators in the field of medici-
ne»9 .
Ehrlich had to wait seven years to get his deserved
award. In 1908, in recognition to his contributions to
immunology, he received the Nobel Prize in Physiology
and Medicine, in the company of the Russian immunologist
and bacteriologist Ilya Ilyich Mechnikov from the Pasteur
Institute of Paris, France2 and during the following years
he obtained several nominations for the same award.
By that time Paul Ehrlich maintained a close long-
standing relationship with the Farbwerke-Hoechst7
company (now Aventis), dedicated to the manufacture
of coloring substances.
Although he always counted with available
laboratories and economic funds, this relationship was
key in achieving the 606 tests carried out on mice, guinea
pigs and rabbits, which culminated with the finding that
the derivative from arsenic which he called salvarsan
(that saves through arsenic) was effective against the
fearsome spirochete that causes syphilis or Treponema
pallidum5, discovered a long time ago by Schaudinn and
Hoffmann in Berlin.
Although the first tests carried out by Ehrlich
discarded the compound used in the 606 trial because of
its apparent ineffectiveness, he decided to try it again.
This decision was influenced by Kitasato, his former
colleague and also by his disciple Hata, who had developed
a method to infect rabbits with the spirochete, which
called the attention of Ehrlich and led him to evaluate it
in infected rabbits2.
While the #606 compound showed high effectiveness
against Treponema pallidum, Ehrlich, cautious with his
discovery, tried in an unsuccessful way, even against his
partner Farbwerke-Hoechst, to restrict access to the
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new medicine, since he considered that before allowing
its general use, it was necessary to conduct a larger
number of clinical trials.
Despite the effectiveness of salvarsan or #606 and
that of the subsequent neosalvarsan or #914, the new
discoveries only were able to face a growing opposition,
which even put him in jail, when the demonstration of its
benefits silenced the voices of his contradictors.
By that time, Ehrlich had already used the term
«magic bullets» to refer to the compounds that
specifically acted against microorganisms that cause
disease. He used to compare these chemical substances
with real bullets that, because of their special affinity for
pathogens, had destructive power over them.
According to Ehrlich, the «magic bullets» should
show a maximum toxicity against parasite and a minimum
against the host, properties that he was in charge of
explaining, in terms of differences related to the chemical
affinity with the cellular protoplasm. This led him to
classify such substances into «parasitotropic» and
«organotropic»5,10. In addition, he coined the term
«chemotherapy» to separate it from the traditional field
of pharmacology to the experimental therapeutic one
that according to him, the intention was to discover
chemicals with specific action on pathogenic infections,
unlike pharmacology, which would address only the
symptoms produced by toxic doses of effective medici-
nes against infectious diseases, once these were tested
in superior healthy animals10.
Ehrlich thought that this apparent bias made that the
pharmacology contribution to the search for truly curative
medicines was very poor, without considering that
thanks to research in this field, medicines such as
antipyretics, analgesics and hypnotics, important in the
symptomatic treatment, have been discovered.
On the other hand, he argued that the benefits of
chemotherapy resided in the experimental induction of
the disease and in the study on the effect of medicines
used against it in animals used for this purpose.
His affirmations received much criticism, not only
because it was felt that the implementation of specific
medicines against particular diseases, as old as the man
himself, e.g, ipecacuana against dysentery and mercury
against syphilis, was not only inseparably linked to the
traditional pharmacology, but also to pharmacological
methods rather than chemotherapy, since medicines
that were used against most common diseases in that
age5, have been more precisely known.
Therefore the birth of the new science of chemo-
therapy was not free of controversy. However, this was
not an obstacle for his followers to continue ahead with
the developing of their own «magic bullets» in tacit
agreement with the decision taken time ago by Paul
Ehrlich, in the sense of bringing dyes from the field of
histology to the chemotherapy´s11, as he had done it with
the methylene blue, red trypan and salvarsan5,10 (although
it was not actually a dye, had a characteristic yellow
hue11).
Some of the most recognized Ehrlich’s followers
were Edgar Lederer (1908-1988) from CNRS in France,
creator of «magic bullets» consisting of muramyl
dipeptides that stimulated the immune response against
viruses, bacteria, protozoan parasites, as well as against
antigens tumors. Reid Hunt (1870-1948), head of the
Laboratory of Hygiene of the Public Health Service of
the United States, precursor entity of NIH and his
student Carl Voegtlin (1879-1960), hard supporters of
chemotherapy against infectious diseases over the
vaccines or serum, and the 1988 Nobel Prize George
Hitchings and 1967 Manfred Eigen also were devoted to
the development of new «magic bullets».
With his discovery of prions, Stanley Prusiner, a
researcher at the University of California, discovered
the fascinating field of brain proteins that, through
changes in their three-dimensional structure could
become «magic bullets» causing infection. This job
game him the award of Paul Erhlich´s prize in 1995 and
the Nobel Prize in 1979.
It is evident that among the findings made by Ehrlich
in the therapeutic field we can find the seed that inspired
the design of synthetic pharmacological agents used in
current research and medical therapy.
The «magic bullets» of salvarsan to treat syphilis, in
which he noted his principle of «selective affinity» (to
eliminate the germ causing disease without body injury),
meant the glory and led to further medicine development
such as sulfonamide, antibiotics and more recently, anti-
tumor medicines including recombinant peptides, as well
as cytotoxic or radioactive agents which may be marked
on a selective way with monocional antibodies.
His persevering character was demonstrated by the
insistence on that his disciples and collaborators repeated
trials conducted for a particular result, over and over
again, before it was published.
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Always interested in the wellbeing of his assistants,
he did not lose his simplicity nor his proverbial affability,
despite the multiple awards and academic honors he
received throughout his existence. In addition to the
Nobel Prize for Physiology and Medicine, he received
honoris causa doctorates at universities of Oxford,
Gottingen and Chicago, Cameron Prizes at the University
of Edinburgh, Honorary of Chemists from Germany and
Honorary Congressional Medical Lisbon prizes, as well
as medals from several countries around the world and
honorary memberships in associations and science
academies12.
Being a strong smoker, his health suffered for several
years after supervising a large-scale delivery of salvarsan
and serum to German army during the First World War
until, in a state of physical and mental exhaustion he died
of a heart attack at 191512.
The deep respect and admiration inspired by Paul
Erhlich to his contemporaries were embodied in the
obituary that Professor Arnold Berliner wrote then in
the newspaper «Naturwissenschaften»13:
«At dawn of history,» so Goethe tells us, «men
held a solemn and sometimes terrifying belief. They
imagined their ancestors seated in silent communion
in great caves in a circle of thrones. When a new soul
entered this company, they would stand and bow to
welcome him if he was worthy enough. The ancestors
are the great men whose services to humanity are
recorded in the Book of Eternity. We can be sure that
they will bow deeply in profound veneration to the
man now entering their presence.»13
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